Nivix Pharmaceuticals Limited has signed an agreement with Muktinath Capital Limited to manage the underwriting of 1,375,000 ordinary shares to be issued to the public. The agreement was signed by Indra baniya, Managing Director of Nivix, and Kabindra Dhwaj Joshi, CEO of Muktinath Capital Limited.
The signing ceremony was attended by Nivix Pharmaceuticals Chairman Mr. Kalidash Poudel, Director Pharmacist Sujan Sigdel, and Chartered Accountant Anil Paudel.
Established in 2017 (BS 2074), Nivix Pharmaceuticals Limited converted into a public limited company on Poush 2, 2081 BS, and has received production and marketing approval from the Department of Drug Administration. Currently, the company produces 56 types of medicines.
The company primarily manufactures medicines used to treat heart disease, diabetes, respiratory issues, liver, and stomach-related illnesses. Additionally, Nivix is engaged in research for new medicines and preparing to expand its product range.
Nivix Pharmaceuticals will issue 1,375,000 shares through an IPO and has signed an underwriting agreement with Muktinath Capital Limited.
